Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Basel, Switzerland
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Obese volunteers (BMI \> 30kg/m2)
Otherwise healthy
Informed Consent as documented by signature (Appendix Informed Consent Form)
You may not be if
Food allergies, food intolerance
Evidence of relevant cardiovascular, pulmonary, renal, hepatic, pancreatic, gastrointestinal, metabolic, endocrinological, neurological, psychiatric or other diseases at screening
Chronic or clinically relevant acute infections
Clinically relevant abnormalities in chemical, haematological or any other laboratory parameters
Participation in drug trials within 2 months before start of the study
Neurological or psychiatric disease or drug or alcohol abuse, which would interfere with the subjects proper completion of the protocol assignment
Pregnancy: although no contraindication pregnancy might influence metabolic state. Women who are pregnant or have the intention to become pregnant during the course of the study are excluded. In female participants of childbearing age not using safe contraception (oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices) a urine pregnancy test is carried out upon screening.
Antibiotic therapy within the last 3 months before inclusion
Substance abuse, alcohol abuse
Inability to follow procedures due to psychological disorders, dementia or insufficient
Knowledge of project language (German).
Participation in another study with investigational drug within the 30 days preceding and during the present study.
Clareo Health | Effect of Daily Intake of SATIOSTAT Over 6 Weeks on Weight Loss, Glucose Tolerance, Gastrointestinal Tolerance and Gut Microbiota.
